12月8日 - ** 药物开发商Recursion Pharma RXRX.O的股价盘前上涨6.2%至5.05美元
** 该公司称，其实验性口服药物 REC-4881 有助于减少一种罕见遗传病--家族性腺瘤性息肉 病--患者结肠中被称为息肉 的 异常增生。
** 在一项早中期试验中，11 名患者中有 9 名在停药 12 周后仍能保持息肉总量的持久减少
** 公司希望将研究范围扩大到更多 18 岁及以上的患者。
** 截至上次收盘，股价累计下跌 30.3
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.